Evidence mapPaperPMID 39871817Full record

ReviewDiabetes, obesity & metabolism2025

Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review.

Alice Y Y Cheng, Robert J Heine, Stefano Del Prato, Jennifer B Green, Vivian Thuyanh Thieu, Meltem Zeytinoglu

Abstract readReview
In one paragraph

Review in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alice Y Y ChengDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-2729-606X
Robert J HeineEli Lilly and Company, Indianapolis, Indiana, USA.
Stefano Del PratoSchool of Medicine, University of Pisa, Pisa, Italy.ORCID 0000-0002-5388-0270
Jennifer B GreenDuke Department of Medicine, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-9967-5352
Vivian Thuyanh ThieuEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-9803-4134
Meltem ZeytinogluEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0002-0158-6109

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a 'legacy effect', where early treatment to reach glycaemic targets is associated with enduring long-term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β-cell function decline, they have been unable to address one of the underlying causal abnormalities-excess adiposity. Here, we review currently available evidence for the beneficial long-term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.

Indexed as

Diabetes Mellitus, Type 2Glycemic ControlHypoglycemic AgentsObesityAdiposityBlood GlucoseBody WeightHumansInsulin ResistanceWeight GainWeight LossBlood GlucoseHypoglycemic Agentsantidiabetic drugantiobesity drugdiabetes complicationsglycaemic controlweight management

Identifiers

PMID39871817
PMCPMC11885087

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.